Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms.

Authors: David J. Casarett, Jessica N. Beliveau, and Michelle S. Arbus
Journal of Palliative Medicine, 6 August 2019

Objectives: To determine the relative contributions of tetrahydrocannabinol (THC) and cannabidiol (CBD) to patients’ self-ratings of efficacy for common palliative care symptoms. Design: This is an electronic record-based retrospective cohort study. Model development used logi…

Opportunities for cannabis in supportive care in cancer.

Authors: Amber S. Kleckner, Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, et al
Therapeutic Advances in Medical Oncology, 1 August 2019

Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symp…

A hunger for hunger: a review of palliative therapies for cancer-associated anorexia.

Authors: Daniel S. Childs, Aminah Jatoi
Annals of Palliative Medicine, January 2019

Cancer-associated anorexia, or loss of appetite, is prevalent, distressing to patients and their families, and associated with poorer outcomes in patients with advanced cancer. A well-defined therapeutic strategy remains to be defined. We present here a review of appetite loss…

Cannabis in palliative care: current challenges and practical recommendations

Authors: Claude Cyr, Maria Fernanda Arboleda, Sunil Kumar Aggarwal, Lynda G. Balneaves, Paul Daeninck, Andrée Néron, Erin Prosk, Antonio Vigano
Annals of Palliative Medicine, October 2018

Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular…

Use of cannabinoids in cancer care: palliative care.

Authors: S.K. Aggarwal
Current Oncology, March 2016

Integrating cim into oncologic palliative care promises to improve overall health-related quality of life, to provide further relief from distressing symptoms and spiritual suffering, and to bring hope to patients and families facing terminal illness. O’Shaughnessy offers the…

The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care.

Authors: Gil Bar-Sela, Marina Vorobeichik, Saher Drawsheh, Anat Omer, Victoria Goldberg, Ella Muller
Evidence-Based Complementary and Alternative Medicine, 2013

BACKGROUND: Cancer patients using cannabis report better influence from the plant extract than from synthetic products. However, almost all the research conducted to date has been performed with synthetic products. We followed patients with a medicinal cannabis license to eval…

Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

Authors: Gregory T. Carter, Aaron M. Flanagan, Mitchell Earleywine, Donald I. Abrams, et al
American Journal of Hospice and Palliative Medicine, August 2011

Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I…

Cannabis use in palliative care – an examination of the evidence and the implications for nurses.

Authors: Anita J Green, Kay De‐Vries
Journal of Clinical Nursing, September 2010

AIM AND OBJECTIVE: Examine the pharmaceutical qualities of cannabis including a historical overview of cannabis use. Discuss the use of cannabis as a clinical intervention for people experiencing palliative care, including those with life-threatening chronic illness such as mu…

Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.

Authors: Vincent Maida, Marguerite Ennis, Shiraz Irani, Mario Corbo, Michael Dolzhykov
Journal of Supportive Oncology, March 2008

A prospective observational study assessed the effectiveness of adjuvant nabilone (Cesamet) therapy in managing pain and symptoms experienced by advanced cancer patients. The primary outcomes were the differences between treated and untreated patients at 30 days’ follow-up, in…